Patents Assigned to Gruenenthal GmbH
  • Publication number: 20240400537
    Abstract: The invention relates to cis-8-(3,5-difluorophenyl)-8-(dimethylamino)-1,3-diazaspiro[4.5]-decan-2-one derivatives, their preparation and use in medicine, particularly in various neurological disorders, including but not limited to pain, neurodegenerative disorders, neuroinflammatory disorders, neuropsychiatric disorders, substance abuse/dependence.
    Type: Application
    Filed: April 24, 2024
    Publication date: December 5, 2024
    Applicant: Gruenenthal GmbH
    Inventors: Sebastian PEIL, Inna SLYNKO, Philipp BARBIE, Nikolay SITNIKOV, Ingo KONETZKI, Mauro MARIGO, David ST. JEAN, Martin PETTERSSON
  • Publication number: 20240252473
    Abstract: Compounds according to general formula (I) act as inhibitors of NaV1.8 and can be used in the treatment of pain.
    Type: Application
    Filed: December 14, 2023
    Publication date: August 1, 2024
    Applicant: Gruenenthal GmbH
    Inventors: Marcel MUELBAIER, Sebastian KRUEGER, Clemens DIALER, Mauro MARIGO, Vipulkumar PATEL
  • Publication number: 20230265078
    Abstract: The invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
    Type: Application
    Filed: July 9, 2021
    Publication date: August 24, 2023
    Applicant: Gruenenthal GmbH
    Inventors: Jo ALEN, Florian JAKOB, Sebastian KRUEGER, Philipp BARBIE
  • Publication number: 20230183184
    Abstract: The invention relates to 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
    Type: Application
    Filed: January 30, 2023
    Publication date: June 15, 2023
    Applicant: Gruenenthal GmbH
    Inventors: Sven KUEHNERT, Rene Michael KOENIGS, Florian JAKOB, Achim KLESS, Anita WEGERT, Paul RATCLIFFE, Ruth JOSTOCK, Thomas KOCH, Klaus LINZ, Wolfgang SCHROEDER
  • Publication number: 20230183222
    Abstract: The invention relates to 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
    Type: Application
    Filed: January 30, 2023
    Publication date: June 15, 2023
    Applicant: Gruenenthal GmbH
    Inventors: Sven KUEHNERT, Rene Michael KOENIGS, Achim KLESS, Anita WEGERT, Paul RATCLIFFE, Ruth JOSTOCK, Thomas KOCH, Klaus LINZ, Wolfgang SCHROEDER
  • Publication number: 20230174520
    Abstract: The invention relates to 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
    Type: Application
    Filed: January 30, 2023
    Publication date: June 8, 2023
    Applicant: Gruenenthal GmbH
    Inventors: Sven KUEHNERT, Rene Michael KOENIGS, Achim KLESS, Anita WEGERT, Paul RATCLIFFE, Ruth JOSTOCK, Thomas KOCH, Klaus LINZ, Wolfgang SCHROEDER, Klaus SCHIENE, Ingo KONETZKI
  • Publication number: 20230174458
    Abstract: A hitherto unknown crystalline form of (?)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence.
    Type: Application
    Filed: January 30, 2023
    Publication date: June 8, 2023
    Applicant: Gruenenthal GmbH
    Inventors: Andreas FISCHER, Helmut BUSCHMANN, Michael GRUSS, Dagmar LISCHKE
  • Publication number: 20230174540
    Abstract: The invention relates to 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
    Type: Application
    Filed: January 30, 2023
    Publication date: June 8, 2023
    Applicant: Gruenenthal GmbH
    Inventors: Sven KUEHNERT, Rene Michael KOENIGS, Florian JAKOB, Achim KLESS, Paul RATCLIFFE, Ruth JOSTOCK, Thomas KOCH, Klaus LINZ, Wolfgang SCHROEDER, Klaus SCHIENE, Anita WEGERT
  • Patent number: 11547678
    Abstract: An aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof and being adapted for oral administration. The composition has excellent storage stability without relying on the presence of high amounts of preservatives.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: January 10, 2023
    Assignee: Gruenenthal GmbH
    Inventors: Ulrich Reinhold, Marc Schiller, Eva Wulsten, Sabine Karine Katrien Inghelbrecht, Roger Carolus Augusta Embrechts, Ulrich Feil
  • Publication number: 20210212967
    Abstract: A method of treating irritable bowel syndrome in a patient in need thereof by administering to said patient a pharmaceutically effective amount of tapentadol.
    Type: Application
    Filed: March 29, 2021
    Publication date: July 15, 2021
    Applicant: Gruenenthal GmbH
    Inventors: Klaus SCHIENE, Petra BLOMS-FUNKE, Thomas CHRISTOPH, Wolfgang SCHROEDER
  • Publication number: 20190350884
    Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient selected from paracetamol and propacetamol.
    Type: Application
    Filed: July 3, 2019
    Publication date: November 21, 2019
    Applicant: Gruenenthal GmbH
    Inventors: Stefanie FROSCH, Klaus LINZ, Klaus SCHIENE
  • Patent number: 10363228
    Abstract: The invention relates to transdermal therapeutic systems (TTS) which include, as active ingredient, the NMDA receptor antagonist memantine or one of its physiologically compatible salts. The TTSs can be produced and used for treating diseases of the central nervous system.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: July 30, 2019
    Assignees: LTS Lohmann Therapie-Systeme AG, Gruenenthal GmbH
    Inventors: René Eifler, Michael Horstmann, Regine Kaufmann, Patrick Mohr, Eric Galia, Wolfgang Prange, Stefan Buller, Klaus Pusecker, Jan Stampfuss, Susanne Stoelben
  • Patent number: 10076510
    Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient, which is selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient, which is a propionic acid derivative selected from the group consisting of ibuprofen, naproxen, ketoprofen, flurbiprofen, fenoprofen, fenbufen, suprofen, pirprofen, indoprofen, tiaprofenic acid, oxaprozin, ibuproxam, flunoxaprofen, alminoprofen, naproxcinod, and the physiologically acceptable salts thereof.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: September 18, 2018
    Assignee: Gruenenthal GmbH
    Inventors: Stefanie Frosch, Klaus Linz, Klaus Schiene
  • Patent number: 9980927
    Abstract: The use of tapentadol (i) in the treatment of pain in a subject suffering from depression and/or from anxiety, and/or (ii) in the treatment or the inhibition of depression or anxiety.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: May 29, 2018
    Assignee: Gruenenthal GmbH
    Inventors: Ilona Steigerwald, Ulrich Jahnel, Thomas Tzschentke
  • Patent number: 9862719
    Abstract: Spirocyclic cyclohexane compounds corresponding to formula I a method for producing them, pharmaceutical compositions containing them, and methods of using them.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: January 9, 2018
    Assignee: Gruenenthal GmbH
    Inventors: Claudia Hinze, Otto Aulenbacher, Bernd Sundermann, Stefan Oberboersch, Elmar Friderichs, Werner Englberger, Babette-Yvonne Koegel, Klaus Linz, Hans Schick, Helmut Sonnenschein, Birgitta Henkel, Valerie Sarah Rose, Michael Jonathan Lipkin
  • Patent number: 9855286
    Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient which is a salicylic acid component selected from the group consisting of acetylsalicylic acid, salicylic acid, salicylamide, ethenzamide, salsalate, dipyrocetyl, benorilate, diflunisal, guacetisal, and the physiologically acceptable salts thereof.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: January 2, 2018
    Assignee: Gruenenthal GmbH
    Inventors: Stefanie Frosch, Klaus Linz, Klaus Schiene
  • Publication number: 20170210734
    Abstract: The invention relates to substituted spirocyclic cyclohexane derivatives which have an affinity for the ? opioid receptor and/or the ORL1 receptor, processes for the preparation thereof, medicaments containing these compounds and the use of these compounds for the preparation of medicaments.
    Type: Application
    Filed: July 14, 2015
    Publication date: July 27, 2017
    Applicant: Gruenenthal GmbH
    Inventors: Anita WEGERT, Sven KUEHNERT, Rene Michael KOENIGS, Bert NOLTE, Klaus LINZ, Stephanie HARLFINGER, Babette-Yvonne KOEGEL, Paul RATCLIFFE, Fritz THEIL, Olga GROEGER, Birgit BRAUN
  • Patent number: 9642801
    Abstract: The present invention provides a dosage form comprising at least one form of tapentadol, with or without a second analgesic, and at least one opioid antagonist, wherein tapentadol is present in an optimal or suboptimal amount and the said antagonist is present in an amount effective to improve the efficacy and or reduce the side effects of tapentadol. The present invention further provides a method of treating pain and pain related conditions by administering to a patient in need thereof, a dosage form comprising at least one form of tapentadol, with or without a second analgesic, and at least one opioid antagonist, wherein tapentadol is present in an optimal or suboptimal amount and the said antagonist is present in an amount effective to improve the efficacy and or reduce the side effects of tapentadol.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: May 9, 2017
    Assignee: Gruenenthal GmbH
    Inventor: Ramesh Sesha
  • Patent number: 9629825
    Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient selected from gabapentinoids and the physiologically acceptable salts thereof.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: April 25, 2017
    Assignee: Gruenenthal GmbH
    Inventors: Stefanie Frosch, Klaus Linz, Thomas Christoph
  • Patent number: 9624209
    Abstract: Substituted phenylureas and phenylamides, processes for their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds for preparing pharmaceutical compositions.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: April 18, 2017
    Assignee: Gruenenthal GmbH
    Inventors: Robert Frank-Foltyn, Gregor Bahrenberg, Thomas Christoph, Klaus Schiene, Jean De Vry, Nils Damann, Sven Frormann, Bernhard Lesch, Jeewoo Lee, Yong-Soo Kim, Myeong-Seop Kim, Derek Saunders, Hannelore Stockhausen